Asthma induced by adrenergic aerosols

doi:10.1016/0021-8707(70)90095-X

Journal of Allergy

Volume 46, Issue 3, September 1970, Pages 162-177

Journal of Allergy

https://doi.org/10.1016/0021-8707(70)90095-X Get rights and content

Abstract

Thirty significantly symptomatic asthmatic patients were divided into 2 groups on the basis of the FEV₁ determined 60 minutes following isoproterenol inhalation. One group consisted of 18 patients who had a 10 per cent or greater increase in the 60 minute postisoproterenol FEV₁ as compared to base-line levels. Eight patients in this group overused isoproterenol aerosols. Discontinuation of isoproterenol by 6 of these 8 patients and 4 other normal users failed to influence asthmatic symptoms. Of the other 12 patients, 9 had a 60 minute FEV₁ near base-line levels, and 3 patients had a precipitous fall in the FEV₁ well below base-line levels after 60 minutes. Nine of these 12 patients greatly overused isoproterenol aerosols. Eight patients discontinued the isoproterenol, with dramatic clinical improvement noted immediately in 7. Pulmonary function studies were repeated in 6 of these patients following cessation of aerosol therapy and confirmed the marked improvement. The clinical data confirmed the induction and persistence of asthma as a result of adrenergic aerosol overuse. The pulmonary function data indicated the 60 minute postisoproterenol FEV₁ is a reliable method of detecting such patients.

References (30)

T.E. Van Metre
Adverse effects of inhalation of excessive amounts of nebulized isoproterenol in status asthmaticus
J. Allerg
(1969)
F.E. Speizer et al.
Investigations into use of drugs preceding death from asthma
Brit. Med. J
(1968)
W.H.W. Inman et al.
Rise and fall of asthma mortality in England and Wales in relation to use of pressurized aerosols
Lancet
(1969)
M.S. Greenberg et al.
Pressurized aerosols in asthma
Brit. Med. J
(1967)
J.F. Keighley
Iatrogenic asthma associated with adrenergic aerosols
Ann. Intern. Med
(1966)
I. Caplin et al.
Complications of aerosol therapy in asthma
Ann. Allerg
(1969)
W.S. Eisenstadt et al.
The adverse effect of adrenergic aerosols in bronchial asthma
Ann. Allerg
(1969)
R.C. Kory et al.
Veterans' Administration-Army cooperative study of pulmonary function
I, Amer. J. Med
(1961)
J.E. Cotes
Lung function
(1965)
J.V. Galgiani et al.
Local and systemic effects from inhalation of strong solutions of epinephrine
J. A. M. A
(1939)

R.L. Benson et al.

Clinical effects of epinephrine by inhalation

J. Allerg

(1948)

F.E. Speizer et al.

Observations on recent increase in mortality in asthma

Brit. Med. J

(1968)

R.E. Reisman et al.

Severe status asthmaticus: Prolonged treatment with assisted ventilation

J. Allerg

(1968)

J.W. Paterson et al.

Isoprenaline resistance and the use of pressurized aerosols in asthma

Lancet

(1968)

J. Lorenzen et al.

Isoprenaline resistance in asthma

Lancet

(1968)

Cited by (78)

Bronchoconstrictor additives in bronchodilator solutions
1999, Journal of Allergy and Clinical Immunology
Nebulized bronchodilator solutions are available in the United States as both nonsterile and sterile-filled products. Sulfites, benzalkonium chloride (BAC), or chlorobutanol are added to nonsterile products to prevent bacterial growth, but there have been reports of contaminated solutions containing preservatives. Ethylenediamine tetraacetic acid (EDTA) is added to some products to prevent discoloration of the solution. With the exception of chlorobutanol, all of these additives are capable of inducing bronchospasm in a concentration-dependent manner. However, it is rarely apparent to the patient or health care provider that the additive diminishes the bronchodilator effects. Older products (eg, isoproterenol and isoetharine) contain enough sulfites to produce bronchospasm in most patients with asthma, even in those without a prior history of sulfite sensitivity. Bronchoconstriction from inhaled BAC is cumulative, prolonged, and correlates directly with basal airway responsiveness. The multidose dropper bottle of albuterol contains 50 μg BAC/dose, which is below the threshold for bronchoconstriction whereas the screwcap unit-dose vial contains 300 μg/dose, which is above the threshold for many patients. If the screwcap product is used in the emergency department, a patient could receive as much as 1800 μg of BAC in the first hour. Three sterile-filled unit dose albuterol products contain no additives, whereas a fourth, (manufactured by Dey Laboratories) contains 300 μg of EDTA, which is also below the threshold dose for bronchoconstriction. Only additive-free sterile solutions should be used for hourly or continuous nebulization of albuterol. The multidose dropper bottle or the Dey product can be used when the interval between doses is longer, whereas the screwcap product should not be used for acute therapy. Ipratropium is available only as a sterile, additive-free unit-dose vial, as is levalbuterol. (J Allergy Clin Immunol 1999;104:S53-60.)
The asthma-like pharmacology and toxicology of (S)-isomers of β agonists
1999, Journal of Allergy and Clinical Immunology
β₂ agonists were designed to emulate the bronchodilation and mast cell suppression effects of human adrenaline, an endogenous neuromediator. Endogenous adrenaline is produced exclusively as the single enantiomer or isomer, (R)-adrenaline, although all selective β₂ agonists are marketed as racemic drugs, composed of a precise 50:50 mixture of R and S isomers. Isomers are compounds that are nonsuperimposable mirror images. The R isomers of β agonists, essentially all congeners of (R)-adrenaline, exhibit the observed bronchodilation and clinical benefit of the racemate. The S isomers of the racemic β agonists are devoid of clinical benefit, are assumed to be benign, and have not been studied until recently. In contradistinction to their assumed benign status, extensive studies with (S)-albuterol have shown that it opposes the bronchodilation effects of (R)-albuterol (levalbuterol), may be proinflammatory, and exhibits the potential to exacerbate airway reactivity to a variety of spasmogens by enhancing contractile responses. Clinically, (S)-albuterol can increase airway reactivity and, because of its slow metabolism, exists in higher and prolonged plasma concentrations than levalbuterol. The sustained presence of (S)-albuterol may help to explain why racemic β agonists have not demonstrated a significant clinical anti-inflammatory potential. Furthermore, the adverse effects (S)-albuterol may contribute to paradoxic bronchospasm and the occurrence of severe reagenic-like reactions seen with racemic albuterol. These adverse effects of (S)-albuterol are completely avoided with single isomer version of (R)-albuterol (levalbuterol). The removal of (S)-albuterol increased the clinical potency of levalbuterol, such that bronchodilator efficacy is achieved at one-fourth the dose of racemic albuterol, but with marked reduction in side effects. Levalbuterol, a third generation β agonist, retains the clinical benefit of racemic albuterol without the proinflammatory and potentially detrimental effects of (S)-albuterol. (J Allergy Clin Immunol 1999;104:S69-76.)
The beta-agonist controversy
1996, Medical Clinics of North America
Long-acting β-agonists, tachyphylaxis, and corticosteroids
1996, Chest
Ketotifen inhibits exacerbation of allergic airway hyperreactivity by racemic salbutamol in the guinea pig
1993, The Journal of Allergy and Clinical Immunology
In passively sensitized anesthetized guinea pigs, intravenous infusion of low doses of antigen ovalbumin induced a marked increased responsivity of the airways to intravenous injection of leukotriene C₄. Sustained infusion of racemic salbutamol intensified responses to leukotriene C₄ both before and after infusion of ovalbumin. Hyperreactivity as a result of infusion of ovalbumin was inhibited by intraduodenal injection of either hydrocortisone or ketotifen at doses that did not diminish responses to leukotriene C₄ in animals not exposed to antigen. Ketotifen, but not hydrocortisone, inhibited the enhanced hyperreactivity associated with infusion of racemic salbutamol.
Exacerbation of Airway Hyperreactivity by (±)Salbutamol in Sensitized Guinea Pigs
1993, The Japanese Journal of Pharmacology
In guinea pigs passively sensitized to ovalbumin, sustained (6 days) subcutaneous infusion of (±)salbutamol (1 mg/kg/day) induced significant airway obstruction and heightened responsivity to airway spasmogens. Of these animals, a substantial proportion (78/235) were too responsive to injected spasmogens to permit infusion of ovalbumin or died following infusion of ovalbumin; yet there were few deaths (2/166) amongst the sensitized animals not exposed to (±)salbutamol. In comparison to the animals not exposed to (±)salbutamol, infusion of ovalbumin led to exaggerated responsivity of the airways to leukotriene C₄, leukotriene E₄, histamine, serotonin and acetylcholine, but not to prostaglandin or bradykinin. The capacity of sustained exposure to high doses of (±)salbutamol to induce airway hyperreactivity to allergic mediators may account for an association between asthma death and regular, excessive use of sympathomimetics.

View all citing articles on Scopus

^∗: Formerly Chief, Allergy Clinic, Brooke General Hospital, Brooke Army Medical Center, Fort Sam Houston, Texas.

View full text

Asthma induced by adrenergic aerosols

Abstract

Adverse effects of inhalation of excessive amounts of nebulized isoproterenol in status asthmaticus

J. Allerg

Investigations into use of drugs preceding death from asthma

Brit. Med. J

Rise and fall of asthma mortality in England and Wales in relation to use of pressurized aerosols

Lancet

Pressurized aerosols in asthma

Brit. Med. J

Iatrogenic asthma associated with adrenergic aerosols

Ann. Intern. Med

Complications of aerosol therapy in asthma

Ann. Allerg

The adverse effect of adrenergic aerosols in bronchial asthma

Ann. Allerg

Veterans' Administration-Army cooperative study of pulmonary function

I, Amer. J. Med

Lung function

Local and systemic effects from inhalation of strong solutions of epinephrine

J. A. M. A

Clinical effects of epinephrine by inhalation

J. Allerg

Observations on recent increase in mortality in asthma

Brit. Med. J

Severe status asthmaticus: Prolonged treatment with assisted ventilation

J. Allerg

Isoprenaline resistance and the use of pressurized aerosols in asthma

Lancet

Isoprenaline resistance in asthma

Lancet